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The prevalence of hepatitis B virus vaccine escape mutants has increased as a consequence of the introduction of global
vaccination programs. Furthermore and as a consequence of the organization of the genome of hepatitis B virus (HBV) into
overlapping reading frames, the selection of polymerase mutants during long-term lamivudine therapy can select viruses with
changes in the overlapping S gene coding for the hepatitis B small antigen (HBsAg). We have investigated the role of
lamivudine in selecting HBV mutants with antigenically altered HBsAg protein using pooled human vaccinee sera in enzyme
immunosorbent assays and radioimmunoassays. HBsAg proteins containing the vaccine escape mutations G145R and
D144E/G145R demonstrated markedly reduced binding to anti-HBs antibody. HBsAg mutants including E164D, W196S,
I195M, M198I, and E164D/I195M (corresponding to the polymerase protein changes of V519L, M550I, L526M/M550V V553I,
and V519L/L526M/M550V) selected during lamivudine treatment also demonstrated reduced binding to anti-HBs antibody.
These findings raise the possibility of lamivudine-resistant mutants arising that possess antigenically distinct HBsAgolymerINTRODUCTION
Hepatitis B vaccination is an effective means of pre-
venting infection by hepatitis B virus (HBV) in susceptible
individuals. The vaccine consists of yeast-derived re-
combinant hepatitis B small antigen (HBsAg) protein and
produces seroconversion in up to 95% of recipients. The
HBsAg protein contains the cysteine-rich “a” determinant
(Emini et al., 1986; Hauser et al., 1987; Milich, 1997;
Peterson et al., 1984; Wallace and Carman, 1997) and it is
this region that is recognised by antibodies that are
elicited by active hepatitis B vaccination and by anti-HBs
antibody present in hepatitis B immune globulin (HBIg)
(Jilg et al., 1984; Szmuness et al., 1980).
The antigenicity of the a determinant has been re-
ported to be dependent on the tertiary structure of this
region of the protein (Carman et al., 1990; Wallace and
Carman, 1997) and other important antigenic epitopes
outside of the a determinant and situated on the surface
of the virus have also been described (Chen et al., 1996).
1 To whom correspondence and reprint requests should be ad-
dressed at: Department of Medicine, Royal Melbourne Hospital, The
University of Melbourne, Level 4 Clinical Sciences Building, Royal305Some of these epitopes are situated downstream of the
a determinant and may also be potential neutralisation
domains (Fig. 1) (Chen et al., 1996).
Mutations in and around the a determinant may result
in an alteration of the antigenicity of the HBsAg protein
and the subsequent failure of anti-HBs antibodies elic-
ited by vaccination to neutralise such mutants (Carman,
1997; Carman et al., 1995, 1996; Coursaget et al., 1987;
Hsu et al., 1999; Karthigesu et al., 1994; Swenson et al.,
1983; Wallace and Carman, 1997; Wands et al., 1986;
Waters et al., 1992). These vaccine escape mutants can
infect vaccinated individuals and are prevalent in coun-
tries with high endemic rates of HBV infection and with
established HBV vaccination programs (Hsu et al., 1999);
in Taiwan, for example, up to 28% of children carrying
HBV harbour these HBsAg mutants (Hsu et al., 1999). It
has been estimated that vaccine escape mutants will
become the dominant HBV quasispecies globally (Wil-
son et al., 2000).
The genome of HBV is organised into overlapping
reading frames with the polymerase gene overlapping
the envelope (s) gene. As a result of this gene arrange-
ment, HBV isolates with polymerase gene mutations that
are selected during the course of antiviral nucleosideproteins. © 2002 Elsevier Science (USA)
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analogue therapy may carry altered neutralisation
epitopes within the HBsAg. Therapy with lamivudine re-
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sults in mutations in the polymerase gene, some of
which are associated with alterations in the a determi-
nant of the HBsAg protein (Lok et al., 2000); these drug-
resistant isolates may have the potential to become
vaccine escape mutants. However, an alteration in the
antigenicity of these lamivudine-selected HBsAg mu-
tants has not been previously demonstrated.
In this study we used human vaccinee antisera to
investigate the differences in antigenicity of the HBsAg
protein isolated from HBV mutants selected by lamivu-
dine.
RESULTS
The binding of antibodies present in human vaccinee
sera to the mutant HBsAg proteins was assessed using
enzyme immunosorbent assays and a radioimmunoas-
say. Sera were tested individually to define individual
variations in antigen–antibody binding and also as
pooled samples. The lamivudine-selected mutant pro-
teins will be referred to according to the amino acid
changes in the HBsAg. To determine that the quality of
antigens produced was consistent, recombinant proteins
were analysed by immune electron microscopy and
SDS–PAGE. The assembly of wild-type HBsAg protein
into 22-nm particles was confirmed by immune electron
microscopy (Fig. 2A). A 24-kD protein could be identified
for the wild-type HBsAg and each mutant protein by
SDS–PAGE and silver staining (Fig. 2B).
Binding of vaccinee serum to recombinant antigens
using enzyme immunoassays (EIA)
The binding of antibody present in individual vaccinee
sera to recombinant HBsAg in an EIA demonstrated that
the binding to mutant proteins was usually reduced rel-
FIG. 1. A diagrammatic representation of the HBsAg protein. The conformation of the two major loops of the “a” determinant is dependent on the
presence of a number of important disulphide bridges (-s-s-). The changes of the vaccine escape mutations D144E and G145R are shown in the
second loop of the a determinant. The changes selected by lamivudine (F158Y, E164D, I195M, W196S, M198I) occur downstream of the a determinant
and are indicated. The carboxy-terminal end of the protein contains two alpha helices (shown here as cylindrical structures), the first of which is
present on the surface of the HBsAg particle (Chen et al., 1996). These alpha helices are separated by a turn and held in this conformation by a
disulphide bridge. The lamivudine-selected amino acid changes I195M, W196S, and M198I occur within this turn and could disrupt the integrity of this
region of the protein. (Adapted from Carman and Wallace, 1997.)
FIG. 2. (A) Analysis of the quality of the HBsAg proteins produced.
After the production and purification of recombinant antigens, immune
electron microscopy of the wild-type HBsAg protein was performed
with goat anti-HBs antibody to demonstrate that proteins had assem-
bled into 22-nm particles. (B) Wild-type and mutant recombinant HBsAg
proteins were also separated by electrophoresis in 12% SDS polyacryl-
amide gels and protein bands detected by silver staining of gels.
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ative to the binding to the wild-type HBsAg (Fig. 3). This
was evident with the binding to the mutants carrying the
G145R and D144E/G145R amino acid changes and that
are recognised as vaccine escape mutants. The vacci-
nee sera also showed varying degrees of reduced bind-
ing to the HBsAg mutants selected during lamivudine
treatment. This was most apparent with the W196S and
the E164D mutants and to a lesser degree with the M198I
and I195M mutants. The binding of vaccinee sera to the
F158Y mutant was similar to the wild-type protein. Some
slight individual variation in the peak levels of antibody
binding to the different HBsAg proteins was noted with
different serum samples tested (compare Figs. 3A and
3B) but this did not correlate with the serum anti-HBs
antibody titre that was measured against wild-type HB-
sAg (1000 IU/ml versus 300 IU/ml) (Fig. 3). Of the nine
individual vaccinee sera examined, the pattern of binding
of anti-HBs antibody was similar (Fig. 3 and data not
shown), although some sera did appear to bind more
strongly to the mutant HBsAg proteins, including the dual
D144E/G145R and the lamivudine-selected mutants
E164D and I195M. These results indicate that antisera
with high-serum anti-HBs antibody titres are unable to
recognise these mutants effectively.
Titration of wild-type and mutant antigen binding by
MEIA
Binding of the recombinant HBsAg proteins was also
tested using a commercial microparticle EIA (IMX HB-
sAg, Abbott Laboratories, North Chicago, IL). Serial two-
fold dilutions of antigens were performed and samples
analysed by IMX assay according to the manufacturer’s
instructions. The mutant HBsAg proteins were poorly
bound using this assay. A marked reduction in binding
with the vaccine escape mutant G145R was detected
(Fig. 4). In comparison to the wild-type HBsAg, the lami-
vudine-selected mutants bound poorly antibody in this
assay (Fig. 4). The binding of anti-HBs antibody binding
to the lamivudine mutants was variable but was reduced
with all of the mutant HBsAg proteins tested (Fig. 4).
These findings supported those of the EIA using human
vaccinee sera and demonstrated that the amino acid
FIG. 3. Binding of individual vaccinee sera to wild-type and recom-
binant yeast-derived HBsAg. EIA plates were coated with 5 g/ml of
recombinant HBsAg and incubated with individual human vaccinee
sera. Anti-HBs antibody titres in serum samples were determined by
IMX (Abbott). The binding pattern of two representative sera to the
mutant proteins is shown. Anti-HBs antibody was present at saturating
levels and despite this failed to bind to several mutant HBsAg proteins.
FIG. 4. Binding of recombinant HBsAg proteins to anti-HBs antibod-
ies in a commercial microparticle EIA. Twofold serial dilutions of the
proteins were performed and the ability to detect the wild-type and
mutant proteins assessed in the Abbott IMX assay. The binding of the
wild-type and the vaccine escape G145R HBsAg proteins to antibodies
in the IMX MEIA are shown (A). The lamivudine HBsAg mutants had a
reduced level of binding than the wild-type HBsAg (A and B).
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changes in HBsAg selected as a consequence of lami-
vudine treatment are sufficient to change the antigenicity
of the HBsAg.
Binding of mutant HBsAg proteins to vaccinee anti-
HBs antibodies by Radioimmunoassay (RIA)
To determine the antigenic relatedness of the HBsAg
proteins, the ability of the mutant HBsAg proteins to
inhibit the binding of anti-HBs antibody to wild-type HB-
sAg protein was determined by competitive antigen–
antibody binding studies. The binding of anti-HBs anti-
bodies present in vaccinee sera to wild-type HBsAg in
the solid phase by RIA was markedly inhibited by the
homologous recombinant wild-type HBsAg protein and
also by the F158Y mutant (Fig. 5). In contrast, the lami-
vudine-selected mutants E164D, I195M, M198I, and
E164D/I195M poorly inhibited the binding of anti-HBs
antibody to the wild-type HBsAg and as a consequence
a higher level of unbound anti-HBs antibody was de-
tected in the RIA (Fig. 5). The IC50 for the inhibition of
binding of anti-HBs antibody to wild-type HBsAg in the
solid phase of the RIA is summarised in Table 1. Little or
no inhibition was observed with the vaccine escape
mutant proteins G145R and D144E/G145R. The greatest
increase in the IC50 was observed with the vaccine es-
cape mutants G145R and D144E/G145R and the E164D/
I195M mutant. A moderate increase was observed with
all polymerase mutants except for F158Y (Table 1).
DISCUSSION
Reduced binding of mutant HBsAg proteins to anti-
HBs antibody
The commercially available HBV vaccines which con-
tain recombinant yeast-derived HBsAg demonstrate effi-
cacy in preventing hepatitis B infection (Emini et al., 1986;
Hadler et al., 1986; Hauser et al., 1987; Hitzeman et al.,
1983; Stevens et al., 1987; Valenzuela et al., 1982). The
levels and durability of the anti-HBs antibody response
elicited by the recombinant yeast vaccine, however, are
lower than those achieved with the HBsAg vaccine de-
rived from the plasma of infected individuals (Jilg et al.,
1988; Papaevangelou et al., 1985; Stevens et al., 1987).
Hepatitis B virus mutants carrying amino acid sequence
changes within the a determinant are not neutralised by
antibodies induced by the recombinant vaccine and
cause infection in vaccinated individuals (Carman et al.,
1995, 1990; Coursaget et al., 1987; Hsu et al., 1999;
Karthigesu et al., 1994; Linnemann and Askey, 1984; Oon
et al., 1995; Swenson et al., 1983; Wands et al., 1986).
In this study we have shown that changes within the
HBsAg protein downstream of the a determinant arising
from lamivudine-selected mutations result in antigeni-
cally distinguishable species. The level and pattern of
binding of individual vaccinee sera to mutant HBsAg
proteins was similar. In addition, the reduction in the
antibody binding to the mutant HBsAg proteins was ev-
ident despite the presence of saturating levels of anti-
HBs antibody. This suggests that the amino acid
changes in the HBsAg selected by lamivudine alter the
antigenicity of the HBsAg and therefore the ability of
anti-HBs antibody to recognise and bind to the protein.
Lamivudine-selected mutations in the S gene have
been identified by sequencing HBV isolates from the
serum of patients on long-term lamivudine (Lok et al.,
2000; Yeh et al., 2000). To date it has only been assumed
that these mutations may have the potential to alter the
antigenicity of the HBsAg protein. Our findings demon-
strate that lamivudine-selected mutations in the HBsAg
produce a decrease in the antigenicity of the protein.
Whether these changes produce HBV species that are
not neutralised by vaccine induced anti-HBs antibody and
therefore result in infection in vaccinated individuals is
FIG. 5. Binding of anti-HBs antibodies to wild-type HBsAg-coated
beads in the presence of mutant HBsAg. Serial dilutions of mutant
HBsAg antigens were incubated with a limiting dilution of anti-HBs
antibody from pooled vaccinee sera. Supernatants were then incubated
with HBsAg-coated beads. The ability of the recombinant mutant HB-
sAg proteins to bind to anti-HBs antibody was analysed by determining
the amount of residual unabsorbed anti-HBs antibody using the AUSAB
RIA (Abbott). The binding of the E164D and W196S lamivudine mutants
is shown in comparison to the wild-type and the G145R vaccine escape
mutant.
TABLE 1
Binding of Anti-HBs Antibody in Pooled Vaccinee Sera to
Recombinant HBsAg Proteins Using the AUSAB RIA
HBV mutants IC50 (g/ml)
Wild type 1.09a
G145R 55.0
D144E/G145R 55.0
F158Y 1.86
E164D 14.86
W196S 8.29
M198I 12.5
I195M 5.26
E164D/I195M 54.53
a Amount of protein required to effect a 50% reduction in the binding
between wild-type HBsAg and anti-HBs antibody in pooled vaccinee
serum.
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yet to be established. However, our findings raise the
possibility that lamivudine-selected HBsAg protein
changes may have the potential to escape neutralisation
by anti-HBs antibody.
We used a variety of commonly performed assays to
demonstrate these antigenic differences. In the assays
used, the G145R and D144E/G145R vaccine escape mu-
tant HBsAg proteins demonstrated reduced binding to
vaccinee anti-HBs antibody. In EIAs, the binding of the
individual vaccinee sera to the HBsAg mutant proteins
was most reduced with the E164D, I195M, W196S, and
M198I lamivudine-selected mutants. The binding of the
mutant F158Y was not reduced.
The different pattern of binding was confirmed when
antigens were tested with a commercial microparticle
EIA. With this assay, the binding of the polymerase-
selected HBsAg mutants to anti-HBs antibody was re-
duced in comparison to the wild-type HBsAg protein (Fig.
3). Antibody binding to the G145R mutant was markedly
reduced.
The binding of pooled vaccinee anti-HBs antibodies to
antigens in their native state in solution using a commer-
cial RIA also revealed a comparable pattern in antibody
binding. These assays were used as competitive radio-
immunoassays to determine if the binding of pooled
vaccinee anti-HBs antibodies to wild-type HBsAg could
be inhibited by preincubating the sera with the mutant
HBsAg proteins. Both vaccine escape mutants, G145R
and D144E/G145R, and the lamivudine-selected mutant
E164D/I195M demonstrated minimal inhibition of binding
of anti-HBs antibody to wild-type HBsAg. Similarly, the
E164D, M198I, I195M, and W196S lamivudine-selected
mutants also showed reduced binding to the anti-HBs
antibodies and therefore poorly inhibited their interaction
with wild-type HBsAg.
The binding of anti-HBs to HBsAg in the in vitro assays
used may be dependent not only on the protein and
epitope sequence but also on the manner in which the
epitopes are presented in the assay. In all of the assays
used in this study, the G145R vaccine escape mutant
HBsAg protein constantly demonstrated reduced binding
to vaccinee anti-HBs. Nevertheless, differences in the
patterns of binding were apparent using solid-phase
ELISA assays where wild-type and mutant HBsAg pro-
teins were coated onto a solid phase under alkaline
conditions compared with results obtained with antigen–
antibody binding studies performed in solution. It is pos-
sible that exposure of additional epitopes or sequestra-
tion of epitopes by a process of partial denaturation of
antigens produced a different pattern of binding than
proteins in solution. Conformational preferences of
epitopes in fluid or solid phase has been previously
described and may play an important role in epitope
functionality (Aleanzi et al., 1996).
Using a commercial microparticle sandwich EIA, the
reduction in binding of the HBsAg mutants to anti-HBs
was greatest with the G145R, M198I, E164D, I195M, and
E164D/I195M mutants, whereas using a commercial RIA
based on competitive binding, the binding of anti-HBs
was markedly reduced with the E164D and W196S mu-
tants and the vaccine escape mutant, G145R, demon-
strated minimal binding to vaccinee anti-HBs.
It should be emphasized however, that despite the
differences observed in the pattern of binding of antibody
to the mutant HBsAg proteins using the different assays,
the binding of the lamivudine-selected HBsAg protein
mutants was consistently reduced when compared to
wild-type protein. Furthermore, these differences were
not the consequence of variability in the quality of mutant
antigens produced. All antigens were produced under
identical conditions. The presence of 24-kD protein was
confirmed by SDS–PAGE and silver staining and assem-
bly into 22-nm particles confirmed by immune electron
microscopy (Fig. 2).
Vaccine escape HBV mutants
Vaccine escape HBV mutants have been reported pre-
viously (Carman et al., 1995; Karthigesu et al., 1994;
Wallace and Carman, 1997) and common vaccine es-
cape variants include G145R, D144A, P142S, Q129H,
I/T126N/A, and M133L (Wallace and Carman, 1997). Fur-
thermore, both monoclonal and polyclonal hepatitis B
immune globulin can select escape mutants, including
A105P, S/T114R, K115T, T118A, Y/C124R, P120E/T, T122N,
Q129H, G130R, N131S, C138Y, S140T, K141I, P142S,
D144A, G145R, and C149R (Wallace and Carman, 1997).
All of these mutants carry changes within the a determi-
nant and cause hepatitis in fully vaccinated individuals
(Carman, 1997; Carman et al., 1996, 1995; Coursaget et
al., 1987; Karthigesu et al., 1994; Swenson et al., 1983;
Wallace and Carman, 1997; Wands et al., 1986; Waters et
al., 1992). The G145R variant is associated with high
levels of viraemia and persistence for periods as long as
8 years, suggesting that this is a stable mutant.
Lamivudine-selected HBsAg protein changes
The HBsAg protein changes that are selected by lami-
vudine therapy occur in regions of the HBsAg protein that
are situated on the surface of the virus and are poten-
tially recognised by anti-HBs antibodies (Fig. 1) (Chen et
al., 1996). Some of these mutations, for example, those
corresponding to the I195M, W196S, and the M198I mu-
tants, affect a conformational region of the HBsAg pro-
tein consisting of two short alpha helices separated by a
disulphide bridge forming a turn (Fig. 1) (Chen et al.,
1996). Sequence changes within this region may alter the
structural integrity of the protein and alter binding to
anti-HBs antibody without affecting the assembly or se-
cretion of the virus (Prange et al., 1995). In addition an
alteration of one epitope of the a determinant may alter
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the binding of antibody to proximal but distinct epitopes
(Waters et al., 1992).
The nature of the anti-HBs antibody response elic-
ited after vaccination may also vary considerably de-
pending on the source of HBsAg (Heijtink et al., 2000).
The binding characteristics of anti-HBs antibody elic-
ited by vaccination with the yeast-derived vaccine are
different from those induced by plasma-derived HBsAg
immunisation (Heijtink et al., 2000), suggesting that
the presentation of immune-reactive epitopes of the
yeast-derived HBsAg is quite different than those on
HBsAg in an infected individual (Heijtink et al., 2000).
The efficacy of the yeast-derived vaccine may there-
fore be reduced in the event of a challenge with
hepatitis B virus, especially if that virus carries an
antigenically altered HBsAg protein.
The clinical significance of the lamivudine-selected
changes within the S gene is not known but mutations
within the HBsAg protein that arise during the course of
lamivudine therapy have been reported (Lok et al., 2000).
The widespread use of nucleoside analogues such as
lamivudine may have the potential to select HBV mutants
that are poorly bound by vaccine-induced anti-HBs anti-
body. Further investigations are warranted to determine
if these HBsAg protein changes will result in infection of
vaccinated individuals and potentially reduce the effi-
cacy of the current HBV vaccine.
MATERIALS AND METHODS
Mutagenesis of the S gene
HBsAg mutants were produced by site-directed mu-
tagenesis using an infectious clone of HBV that includes
all of the major reading frames of HBV. Mutagenesis was
performed using the Quickchange Site Directed Mu-
tagenesis system, according to the manufacturer’s in-
structions (Stratagene, La Jolla, CA). The HBsAg muta-
tions were obtained from a HBV sequence database
developed at the Victorian Infectious Diseases Refer-
ence Laboratory (VIDRL) based on viral isolates from the
sera of patients treated with lamivudine. Several of these
mutants have been previously reported (Bartholomew et
al., 1997; De Man et al., 1998; Ling and Harrison, 1999;
Tipples et al., 1996; Wallace and Carman, 1997). The S
gene mutations with the respective changes in the over-
lapping polymerase gene were confirmed by DNA se-
quencing. The sequence changes of HBV mutants are
summarised in Table 2.
Plasmid construction
The full-length S genes carrying potential vaccine es-
cape mutations were amplified by PCR using primers
with 5 Sma1 and 3 Cla1 restriction sites. The PCR
fragments were separated by agarose gel electrophore-
sis and purified using a Prep-A-Gene kit (Bio-Rad, CA)
according to the manufacturer’s instructions. The 5
primer was designed to introduce a hexahistidine tag at
the amino terminal end of the S protein. The primer
sequences used are as follows: Forward primer: 5TCC
CCC GGG CAT CAT CAT CAC CAT CAC ATG GAG AAC
ATC ACA TCA GG 3; Reverse primer: 5CCA TCG ATT
TAG GGA ATA ACC CCA TC 3. The reverse primer used
for the M550I mutant was identical to the primer se-
quence above except that it included a 3 Kpn1 restric-
tion site. The sequence of this primer (reverse primer 2)
was 5CGG GAT CCT TAG GGA ATA ACC CCA TC 3.
Purified S gene products were subcloned into pCRScript
(Stratagene) with 100 u of T4 DNA ligase (New England
Biolabs, MA) supplemented with 1 mM ATP. Plasmids
were transformed into Escherichia coli (DH5) by heat
TABLE 2
Mutants of HBV and a Comparison of Their Amino Acid Changes within the Wild-Type Polymerase and HBsAg Proteinsa
Mutant virus
Position within the polymerase protein at which
sequence change occurs
Position within the HBsAg protein at which sequence change
occurs
499 512 519 526 550 553 144 145 158 164 195 196 198
Wild type G/W F V L M V D G F E I W M
D144E/G145R E E R
G145R Q R
F158Y L Y
E164D L D
I195M V M
I195M M V M
W196S I S
M198I I I
E164D/I195M L M V D
a Positions within the wild-type HBV polymerase and HBsAg at which sequence changes occur within the mutant proteins. The amino acid changes
are shown in single letter code for the individual mutants.
310 TORRESI ET AL.
shock and fidelity of the clones confirmed by DNA se-
quencing.
The hexahistidine-tagged S genes were digested with
Sma1 and Cla1 (or Kpn1 for the M550I mutant), sepa-
rated by agarose gel electrophoresis, purified with Prep-
A-Gene (Bio-Rad), and finally subcloned into the yeast
expression vector yEPpFlag (Eastman Kodak Co.). Fidel-
ity of the clones was again confirmed by DNA sequenc-
ing.
Transformation of yeast cells
Wild-type and mutant S genes were transformed into
Saccharomyces cerevisia using PEG–bicine transforma-
tion under tryptophan selection according to the manu-
facturer’s instructions (Eastman Kodak Co.). Briefly,
BJ3505 cells (S. cerevisiae) were grown for 24 h at 28°C
in 10 ml YPD medium (2% glucose, 2% peptone, 1% yeast
extract). This culture was used to inoculate a further 90
ml YPD medium and incubated at 28°C for 4 h or until the
OD600 had reached a value of 0.6. An aliquot of cells (10
ml) was centrifuged for 5 min at 3200 g (Beckman GPR
centrifuge) and resuspended in 5 ml SBEG medium (1 M
sorbitol, 10 mM bicine, pH 8.35, 3% polyethylene glycol
1000, Sigma), and the cells sedimented by centrifugation
for 5 min at 3200 g. The pellet was resuspended in 200
l of SBEG medium before incubating at 28°C for 5 min
without shaking.
An amount (1.0 g) of plasmid DNA of each mutant
was added to separate aliquots of cells in SBEG before
incubating for a further 10 min at 28°C with shaking. The
transformation mixture was incubated at 80°C for a
further 45 min, followed by thawing at 37°C and incubat-
ing for 1 h without shaking. Following this incubation, 2
ml NB buffer (0.15 M NaCl, 10 mM bicine, pH 8.35) was
added and the cells sedimented by centrifugation as
above. The cells were resuspended in 500 l NB buffer
and a 100-l aliquot plated on selective CSM-Trp plates
[0.67% yeast nitrogen base (without amino acids), 2%
dextrose, 0.074% CSM-Trp amino acid mixture (Bio 101),
100 mg/l glutamic acid, 400 mg/l serine, 2% agar].
Expression of recombinant HBsAg proteins
Recombinant HBsAg proteins were expressed by in-
oculating 10 ml CSM-Trp medium and incubating for 48 h
at 28°C with shaking. A 2.5-ml aliquot of this culture was
used to inoculate 47.5 ml YPSHM medium (1% dextrose,
3% glycerol, 1% yeast extract, 8% peptone, 20 mM cal-
cium chloride) and incubated for 72 h at 28°C with
shaking at 175 rpm.
Recovery of HBsAg by nondenaturing lysis of yeast
cells
Following the expression of HBsAg proteins, 50 ml
cultures of yeast cells were sedimented by centrifugation
for 15 min at 3200 g. The pellet was resuspended in 1 ml
disruption buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7.0
with 0.1% Triton X-100). A 400-l aliquot of resuspended
cells was transferred to a 10-ml tube and 1.6 ml glass
beads was added. The mixture was vortexed for 1 min
and then incubated on ice for 2 min. These two steps
were repeated five times before allowing the glass
beads to settle and before collecting the supernatant
(cell lysate). A further 1.5 ml disruption buffer was added
to the lysate and the mixture inverted 10 times before
allowing the glass beads to settle. The supernatant was
collected and the cell lysates clarified by centrifugation
for 1 h at 10,000 g. An aliquot of the supernatant was
tested for HBsAg using a commercial microparticle en-
zyme immunoassay (MEIA; IMX, Abbott Laboratories)
before proceeding with purification of recombinant pro-
teins.
Protein purification
The recombinant HBsAg proteins were purified by
immobilised metal affinity chromatography using Talon
resin (Clontech, Palo Alto, CA). A 4-ml volume of resin
was washed in 50 mM NaH2PO4 with 300 mM NaCl, pH
7.0 before sedimenting the resin for 5 min at 700 g. The
clarified cell lysate was added to the resin and gently
mixed for 20 min at room temperature. The mixture with
the hexahistidine-tagged HBsAg bound to the resin was
centrifuged for 5 min at 700 g. The resin was then
washed with 10 bed volumes of wash buffer (50 mM
NaH2PO4 with 300 mM NaCl, pH 7.0) at room tempera-
ture for 10 min on a rotating wheel before centrifugation
for 5 min at 700 g. The supernatant was discarded and
the resin washed a further two times. The resin mixture
was resuspended in one bed volume of wash buffer and
transferred to a gravity-flow column. The resin was
washed twice with five bed volumes of wash buffer
followed by three washes with wash buffer containing 10
mM imidazole and one final wash with wash buffer
containing 25 mM imidazole. The hexahistidine-tagged
HBsAg protein was finally eluted and collected in 500-l
fractions using four bed volumes of elution buffer (45 mM
NaH2PO4, 150 mM NaCl, 100 mM imidazole, pH 7.0). An
aliquot of each eluate was tested for HBsAg using the
commercial IMX assay (Abbott). Proteins in strongly re-
active fractions were used in an EIA format or concen-
trated by ultrafiltration using Centricon 30 filters (Amicon,
MA). Analysis of proteins by SDS–PAGE and silver stain-
ing demonstrated that proteins were 90% pure. All
proteins were quantitated by Lowry assay (Protein DC,
Bio-Rad). The quality of proteins produced was analysed
by SDS–PAGE and silver staining with Silver Stain Plus
(Bio-Rad) according to the manufacturer’s instructions.
Finally, immune electron microscopy was performed to
ensure that the HBsAg proteins had formed 22-nm par-
ticles. In brief, recombinant HBsAg was immunoprecipi-
tated overnight at 4°C with goat anti-HBs antibody (Dako,
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CA). Immune complexes of anti-HBs–recombinant HB-
sAg were stained with 3% phosphotungstic acid (pH 7.0)
on a 400-mesh Formvar carbon-coated copper grid and
visualized using a CM12 STEM electron microscope
(Philips, Eindhoven, Holland).
Binding of antibodies to mutant HBsAg proteins in an
enzyme immunoassay
Sera were collected from volunteers who had been
vaccinated with commercially available HBV vaccines
(HBVax II, Merk Sharp Dohme or Engerix B, Glaxo Smith
Kline). The binding of anti-HBs antibody to recombinant
HBsAg was analysed by EIA. Plates (Maxisorp, Nunc)
were coated with recombinant antigens at the concen-
trations indicated. All antigens were prepared in a coat-
ing buffer (15 mM Na2CO4, 35 mM NaHCO3, 0.21 mM
NaCl, pH 9.4) and held overnight at 4°C.
The antigen solutions were removed and plates incu-
bated for 1 h at 37°C with blocking solution [10% skim
milk powder and 0.5% Tween 20 in phosphate-buffered
saline (PBS)]. Human vaccinee sera and goat anti-human
horseradish peroxidase (HRP) conjugate (Dako) were
prepared in antibody diluent buffer (10% skim milk pow-
der and 0.5% Tween 20 in PBS). Vaccinee sera were
incubated with antigen-coated plates for 2 h and the
anti-human–HRP conjugate (Dako) was incubated for 1 h
at room temperature. Plates were washed using PBS
containing 0.05% Tween 20 between these treatments.
Absorbance was read at 405 nm.
Titration of recombinant HBsAg protein binding by
IMX MEIA
The panel of wild-type and mutant recombinant HBsAg
proteins was examined for antigenicity using a commer-
cial microparticle enzyme immunoassay (IMX, MEIA, Ab-
bott Laboratories) according to the manufacturer’s in-
structions. Briefly, serial dilutions of the proteins were
prepared in PBS and added to monoclonal anti-HBs
antibody-coated microparticles. Biotinylated goat anti-
HBs antibody was added, forming antigen–antibody
complexes bound to microparticles. The complexes are
bound to a glass fibre matrix and rabbit anti-biotin–
alkaline phosphatase conjugate added, followed by the
substrate 4-methylumbelliferyl phosphate. Fluorescence
was then measured by the MEIA optical assembly pro-
vided by Abbott Laboratories.
Binding of antibody to mutant HBsAg proteins by RIA
Sera were collected from volunteers who had been
vaccinated with recombinant HBV vaccine. Sera were
pooled and anti-HBs antibody titres determined using
the IMX assay. A limiting dilution, determined by perform-
ing serial twofold dilutions of serum prepared in anti-HBs
antibody negative serum, was defined as the highest
dilution of pooled vaccinee sera that gave an antibody
titre one dilution above the cutoff of the anti-HBsAg IMX
assay. Limiting dilutions of pooled vaccinee sera were
then incubated with serial dilutions of wild-type or mu-
tant recombinant HBsAg proteins for 1 h at 37°C. The
difference in the binding of anti-HBs antibody to wild-
type and mutant HBsAg proteins was then determined by
detecting residual anti-HBs antibody, i.e., that which was
not absorbed by the recombinant HBsAg proteins, by
incubating samples overnight with HBsAg-coated plastic
beads from the AUSAB RIA kit (Abbott Laboratories)
according to the manufacturer’s instructions. Briefly, fol-
lowing an overnight incubation, residual anti-HBs anti-
body is bound to the HBsAg-coated beads. After exhaus-
tive washing, only antibody bound directly to the HBsAg-
coated beads remains and this is detected by the
addition of 125I-labelled anti-human IgG and bound 125I-
labelled HBsAg determined.
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